Subsequently, we analyzed the methylation of RASSF2 and RASSF5A promoter in 31 primary thyroid carcinomas (3 MTC, 10 FTC, 12 PTC and 6 UTC), 10 follicular adenomas, 12 goiters and 12 normal thyroid controls (Fig. 3 and Tab. This evidence concerns the gene RASSF2 and thyroid gland carcinoma.